Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Open access

Association of total and brain-derived Alzheimer's disease plasma biomarkers with brain amyloid deposition in a community-based sample

Muge Akinci Froogh Aziz D. Guzman Lina Cheung Jian X Kong Stephanie A Silver Joseph P. Eimicke Sabrina Simoes Jeanne A. Teresi A. Brickman P. Lao J. Luchsinger
Jul 2026 · medRxiv · 0 citations
Medicine

TL;DR

In a community-based sample, BD-p-tau217 emerged as the plasma biomarker most strongly associated with brain A{beta} deposition, although this association may be attenuated in the presence of moderate/severe kidney dysfunction or kidney failure.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Dec 2025

Developing Topics.

BACKGROUND Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use. METHOD Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...

Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al. · 0 citations
Sep 2026

Validation of plasma core biomarkers of Alzheimer's disease: A multicenter study in usual practice conditions

Plasma p-tau217 is established as a first-choice biomarker for the early detection of AD pathology in specialized clinical settings, displaying excellent diagnostic accuracy and minimal site-related variability.

A. Sánchez-Soblechero, A. Villarejo, M. Carreras et al. · 0 citations
Open access Aug 2026

Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease

Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET thres...

Yasaman Abtahi, Nikki Ghadiminia, Hamide Nasiri et al. · 0 citations
Aug 2026

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.

OBJECTIVE Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...

Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al. · 0 citations
Open access Aug 2026

Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort

Plasma p-Tau217 showed a stronger association with cerebral amyloid pathology than eZIS indices in this elderly MCI cohort, and eZIS may provide complementary information regarding downstream neurodegenerative and cerebrovascular processes that are not directly captured by plasma biomarkers.

I-Lun Huang, Hiroshi Matsuda, Ya-Tang Pai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.